Skip to main content

Table 2 TTF rate point estimates and 95% confidence intervals for the 30 mg, 40 mg and 50 mg vinorelbine groups (TTF refers to time from treatment initiation to discontinuation for any reason)

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

 

Patients (%) on treatment

 

Vinorelbine dose arm (mg)

At 4 months

 

At 6 months

 
  

p value

 

p value

30

25.9% (11.1-46.2%)

0.56

22.2% (8.6-57.7%)

0.39

40

33.3% (15.6-55.6%)

8.3% (1.0-27.0%)

50

18.2% (5.2-20.3%)

13.6% (2.9-34.9%)